Bebenek Marek, Duś Danuta, Koźlak Joanna
1st Department of Surgical Oncology, Lower Silesian Oncology Center, Wrocław, Poland.
Med Sci Monit. 2006 Nov;12(11):CR457-61.
Several studies on breast cancer patients indicate that Fas/FasL status may have a significant impact on patient survival, but their conclusions are still controversial. The aim of this study was to determine the prognostic value of Fas and Fas ligand (FasL) expressions in the early stages of breast cancer.
MATERIAL/METHODS: One hundred and eight patients aged 35-77 years (median: 58), mostly with stage I or II tumors, were analyzed.
Significant associations were noted between Fas expression and lymph node involvement (p<0.0001) or the number of recurrences (p=0.02) and between the presence of FasL and the histological grade of tumor (p=0.007). A five-year follow-up was available for 80/108 (84%) patients: 52/66 (79%) with Fas-positive and 28/42 (67%) with Fas-negative tumors (p=0.102). Considering the expression of FasL, 31/45 (69%) patients with positive and 50/63 (79%) with negative immunostaining have survived five years following surgery (p=0.157).
The study demonstrated that the components of the Fas/FasL system are associated with the clinical outcome of breast cancer and consequently should be considered in prognosis, complementing the existing conventional factors.
多项针对乳腺癌患者的研究表明，Fas/FasL状态可能对患者生存有显著影响，但其结论仍存在争议。本研究旨在确定Fas和Fas配体（FasL）表达在乳腺癌早期阶段的预后价值。
材料/方法：分析了108例年龄在35 - 77岁（中位数：58岁）的患者，大多数为I期或II期肿瘤。
Fas表达与淋巴结受累（p<0.0001）或复发次数（p = 0.02）之间以及FasL的存在与肿瘤组织学分级之间存在显著关联（p = 0.007）。80/108（84%）例患者有5年随访数据：Fas阳性肿瘤患者中52/66（79%）例，Fas阴性肿瘤患者中28/42（67%）例（p = 0.102）。考虑FasL的表达，免疫染色阳性的31/45（69%）例患者和阴性的50/63（79%）例患者术后存活了5年（p = 0.157）。
该研究表明，Fas/FasL系统的组成部分与乳腺癌的临床结局相关，因此在预后评估中应予以考虑，作为现有传统因素的补充。
